As coronary computed tomography angiography (CCTA) progresses towards becoming the primary imaging modality for not only diagnostic purposes, but also for clinical trial endpoints, there is a need to address the requirements for generating high-quality CCTA image data to ensure accurate and robust CAD assessments. This guest column identifies considerations for the use of CCTA in clinical trials involving Atherosclerotic Cardiovascular Disease (ASCVD).